镭-223用于去势抵抗性前列腺癌骨转移的治疗 - Suppr

Radium-223 for the Management of Bone Metastases in Castration-Resistant Prostate Cancer.

作者信息

Cox Heather, Hames Megan, Benrashid Mona

机构信息

Novant Health Oncology Specialists, Greensboro/Winston-Salem, North Carolina; Vanderbilt University Medical Center, Nashville, Tennessee.

出版信息

J Adv Pract Oncol. 2015 Nov-Dec;6(6):565-70. Epub 2015 Nov 1.

PMID:27648346

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5017547/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/578a/5017547/d7e3430d4cf5/jadp-06-565-g01.jpg

相似文献

Radium-223 for the Management of Bone Metastases in Castration-Resistant Prostate Cancer.

J Adv Pract Oncol. 2015 Nov-Dec;6(6):565-70. Epub 2015 Nov 1.

Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial.

Lancet Oncol. 2014 Jun;15(7):738-46. doi: 10.1016/S1470-2045(14)70183-4. Epub 2014 May 13.

Histopathology of castration-resistant prostate cancer confirms changes in bone metastasis during radium-223 treatment: A case report.

Urol Case Rep. 2020 May 3;32:101230. doi: 10.1016/j.eucr.2020.101230. eCollection 2020 Sep.

Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial.

Lancet Oncol. 2019 Mar;20(3):408-419. doi: 10.1016/S1470-2045(18)30860-X. Epub 2019 Feb 6.

Re-treatment with radium-223: first experience from an international, open-label, phase I/II study in patients with castration-resistant prostate cancer and bone metastases.

Ann Oncol. 2017 Oct 1;28(10):2464-2471. doi: 10.1093/annonc/mdx331.

A phase II randomized trial of metastasis-directed therapy with alpha emitter radium-223 in men with oligometastatic castration-resistant prostate cancer (MEDAL).

BMC Urol. 2023 Mar 6;23(1):33. doi: 10.1186/s12894-023-01202-z.

Radium-223 dichloride for the treatment of castration-resistant prostate cancer with symptomatic bone metastases.

Expert Rev Clin Pharmacol. 2017 Aug;10(8):809-819. doi: 10.1080/17512433.2017.1345624. Epub 2017 Jul 3.

Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial.

Lancet Oncol. 2014 Nov;15(12):1397-406. doi: 10.1016/S1470-2045(14)70474-7. Epub 2014 Oct 17.

Radium-223 in the therapeutic sequence of metastatic castration-resistant prostate cancer.

Actas Urol Esp (Engl Ed). 2018 May;42(4):227-237. doi: 10.1016/j.acuro.2017.05.005. Epub 2017 Jul 12.

Radium-223 Within the Evolving Treatment Options for Metastatic Castration-resistant Prostate Cancer: Recommendations from a European Expert Working Group.

Eur Urol Oncol. 2020 Aug;3(4):455-463. doi: 10.1016/j.euo.2019.02.007. Epub 2019 Mar 26.

本文引用的文献

Radium-223 in the treatment of osteoblastic metastases: a critical clinical review.

Int J Radiat Oncol Biol Phys. 2015 Apr 1;91(5):898-906. doi: 10.1016/j.ijrobp.2014.12.061.

Systemic therapy in men with metastatic castration-resistant prostate cancer:American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline.

J Clin Oncol. 2014 Oct 20;32(30):3436-48. doi: 10.1200/JCO.2013.54.8404. Epub 2014 Sep 8.

Radium-223 chloride: Extending life in prostate cancer patients by treating bone metastases.

Clin Cancer Res. 2013 Nov 1;19(21):5822-7. doi: 10.1158/1078-0432.CCR-13-1896. Epub 2013 Sep 19.

Alpha emitter radium-223 and survival in metastatic prostate cancer.

N Engl J Med. 2013 Jul 18;369(3):213-23. doi: 10.1056/NEJMoa1213755.

Tackling the bone with alpha emitters in metastatic castration-resistant prostate cancer patients.

Eur Urol. 2013 Feb;63(2):198-200. doi: 10.1016/j.eururo.2012.09.062. Epub 2012 Oct 5.

Radiation-based approaches for therapy and palliation of advanced prostate cancer.

Curr Opin Urol. 2012 May;22(3):183-9. doi: 10.1097/MOU.0b013e32835259d2.

NCCN clinical practice guidelines in oncology: prostate cancer.

J Natl Compr Canc Netw. 2010 Feb;8(2):162-200. doi: 10.6004/jnccn.2010.0012.

Combined use of zoledronic acid and 153Sm-EDTMP in hormone-refractory prostate cancer patients with bone metastases.

Eur J Nucl Med Mol Imaging. 2008 Apr;35(4):756-65. doi: 10.1007/s00259-007-0659-z. Epub 2007 Dec 22.

Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases.

Bone. 2006 Jul;39(1):35-41. doi: 10.1016/j.bone.2005.12.004. Epub 2006 Jan 24.

Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer.

Urology. 2004 May;63(5):940-5. doi: 10.1016/j.urology.2004.01.034.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Radium-223 for the Management of Bone Metastases in Castration-Resistant Prostate Cancer.

作者信息

机构信息

出版信息

相似文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

本文引用的文献